Synthesis and 64Cu-Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold.

IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-05-21 DOI:10.1002/cmdc.202500243
Marie M Le Roy, Patricia Le Saëc, Michel Chérel, Alain Faivre-Chauvet, Thibault Troadec, Raphaël Tripier
{"title":"Synthesis and <sup>64</sup>Cu-Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold.","authors":"Marie M Le Roy, Patricia Le Saëc, Michel Chérel, Alain Faivre-Chauvet, Thibault Troadec, Raphaël Tripier","doi":"10.1002/cmdc.202500243","DOIUrl":null,"url":null,"abstract":"<p><p>CXCR4 is a transmembrane receptor overexpressed in a large variety of cancer cells. In addition to classical antibody- and peptide-targeting for the development of positron emission tomography (PET) radiopharmaceuticals, this receptor possesses a range of small organic inhibitors that can be exploited. These are based mainly on nitrogen-rich scaffolds, such as AMD070, and cyclic polyamines, such as cyclam, in the AMD3100 skeleton. The latter has been explored as a direct <sup>64</sup>Cu chelator, but examples of CXCR4 PET imaging with small organic targeting units are still scarce in the literature. Herein, the synthesis of two novel CXCR4-directed radiopharmaceuticals is described, combining the AMD070 scaffold as a targeting unit and bifunctional te1pa macrocycle as a strong <sup>64</sup>Cu chelator. The synthesis of the conjugates and optimization of <sup>64</sup>Cu-radiolabeling are presented, opening the way for future in vitro and in vivo studies.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e2500243"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

CXCR4 is a transmembrane receptor overexpressed in a large variety of cancer cells. In addition to classical antibody- and peptide-targeting for the development of positron emission tomography (PET) radiopharmaceuticals, this receptor possesses a range of small organic inhibitors that can be exploited. These are based mainly on nitrogen-rich scaffolds, such as AMD070, and cyclic polyamines, such as cyclam, in the AMD3100 skeleton. The latter has been explored as a direct 64Cu chelator, but examples of CXCR4 PET imaging with small organic targeting units are still scarce in the literature. Herein, the synthesis of two novel CXCR4-directed radiopharmaceuticals is described, combining the AMD070 scaffold as a targeting unit and bifunctional te1pa macrocycle as a strong 64Cu chelator. The synthesis of the conjugates and optimization of 64Cu-radiolabeling are presented, opening the way for future in vitro and in vivo studies.

基于AMD070支架的小型有机放射缀合物的合成及64cu放射性标记策略。
CXCR4是一种在多种癌细胞中过表达的跨膜受体。除了用于开发正电子发射断层扫描(PET)放射性药物的经典抗体和肽靶向外,该受体还具有一系列可开发的小有机抑制剂。这些主要基于富含氮的支架,如AMD070,和环多胺,如AMD3100骨架中的cyclam。后者已被探索为直接的64Cu螯合剂,但在文献中使用小有机靶向单位的CXCR4 pet成像的例子仍然很少。本文中,我们描述了两种新型cxcr4定向放射性药物的合成,将AMD070支架作为靶向单位,将双功能te1pa大环作为强64Cu螯合剂。本文介绍了64cu -放射性标记的共轭物的合成和优化,为64cu -放射性标记的进一步体外和体内研究开辟了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信